ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol D, Freudensprung U, Plitz T, van Beek J, ATON Trial Group J Neurol Sci. 2015 Feb 17. PMID: 25758472. Abstract CommentRecommendBookmarkWatch